mRNA-5671

mRNA-5671
Vaccine description
TargetCancer driven by G12D, G12V, G13D or G12C mutation in the KRAS gene
Vaccine typemRNA
Clinical data
Routes of
administration		Intramuscular

mRNA-5671 also known as V941 is a cancer vaccine candidate developed by Moderna.[1] It is a tetravalent vaccine that targets G12D, G12V, G13D or G12C driver mutations in the KRAS gene.[2] It is currently being evaluated for the treatment of either non-small cell lung cancer, colorectal cancers with microsatellite instability, or pancreatic adenocarcinoma, all with confirmed KRAS driver mutations.[3]

In 2021 Merck dropped the trial,[4][5] and clinicaltrials.gov study NCT03948763 ended on August 25, 2022.[6] As of May 2024, no further progress on this vaccine has been announced.

References

  1. ↑ "mRNA 5671". AdisInsight. Springer Nature Switzerland AG.
  2. ↑ "mRNA-derived KRAS-targeted vaccine V941". National Cancer Institute Dictionaries. National Institutes of Health, U.S. Department of Health and Human Services.
  3. ↑ Clinical trial number NCT03948763 for "A Study of mRNA-5671/V941 as Monotherapy and in Combination With Pembrolizumab (V941-001)" at ClinicalTrials.gov
  4. ↑ Taylor, Nick Paul (February 24, 2022). "Merck cuts ties to Moderna's early-phase KRAS vaccine, leaving mRNA specialist to mull next steps | Fierce Biotech". Fiercebiotech.com. Retrieved July 16, 2026.
  5. ↑ "Moderna Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides Business Updates". Investors.modernatx.com.
  6. ↑ "A Phase 1, Open-Label, Multicenter Study to Assess the Safety and Tolerability of mRNA-5671/V941 as a Monotherapy and in Combination with Pembrolizumab in Participants with KRAS Mutant Advanced or Metastatic Non-Small Cell Lung Cancer, Colorectal Cancer or Pancreatic Adenocarcinoma". Cliniclatrials.gov. 5 September 2022.


This page is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.